NE
NEUP.US Neuphoria Therapeutics Inc
- Market cap
- USD 13.8M
- P/E
- -
- P/B
- 0.55x
- ROE
- -54.7%
- Dividend yield
- -
- Fundamental score
- -
Ratios use the latest price and the fiscal year ending Jun 2026.
Is NEUP.US undervalued?
Graham numberThe Graham number of Neuphoria Therapeutics Inc cannot be estimated reliably (it needs positive earnings and book value).
Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?
Neuphoria Therapeutics Inc fundamental analysis
No fundamental analysis for Neuphoria Therapeutics Inc yet.
Neuphoria Therapeutics Inc stock price
Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.
About Neuphoria Therapeutics Inc
Neuphoria Therapeutics Inc., a clinical stage biopharmaceutical company, develops novel allosteric ion channel modulators for patients with serious central nervous system disorders in Australia. Its lead product candidate is BNC210, an oral, proprietary, selective negative allosteric modulator of the alpha7 nicotinic acetylcholine receptor for post-traumatic stress disorder. The company also develops Merck alpha7 positive allosteric modulators. It has a research collaboratio…
Full company profileNeuphoria Therapeutics Inc financial statements
Neuphoria Therapeutics Inc annual financial statements (USD; K = thousand, M = million, B = billion, T = trillion)
| Item | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|---|---|---|---|
| Income Statement | ||||||||||
| Revenue | 27.1M | 11.9M | 7.40M | 32.1K | 928K | 383K | 0.00 | 0.00 | 15.6M | 1.17M |
| Gross Profit | 2.84M | -13.4M | 2.68M | 32.1K | -1.27M | -9.98M | -671K | -663K | 15.6M | 1.17M |
| Operating Income | -13.8M | -21.3M | -10.8M | -6.19M | -8.96M | -31.0M | -33.1M | -26.8M | -1.13M | -16.5M |
| EBITDA | -3.67M | -22.4M | -11.2M | -1.23M | -4.51M | -30.8M | -31.5M | -26.0M | -466K | -15.8M |
| Net Income | -5.19M | -18.4M | -6.77M | -4.89M | -6.53M | -22.9M | -32.2M | -15.5M | -370K | -13.5M |
| EPS | -0.13 | -0.46 | -0.16 | -0.11 | -0.10 | -0.20 | -0.26 | -0.10 | -0.19 | -3.06 |
| Balance Sheet | ||||||||||
| Total Assets | 64.6M | 47.8M | 37.6M | 23.7M | 40.8M | 65.3M | 19.4M | 27.6M | 28.6M | 28.7M |
| Total Liabilities | 33.5M | 35.3M | 25.2M | 15.0M | 5.01M | 8.40M | 4.74M | 10.2M | 9.59M | 4.11M |
| Shareholders' Equity | 31.1M | 12.5M | 12.4M | 8.71M | 35.8M | 56.9M | 14.7M | 17.5M | 19.0M | 24.6M |
| Cash & Short-term Investments | 33.4M | 18.7M | 10.2M | 3.15M | 21.4M | 33.6M | 8.06M | 12.6M | 14.2M | 19.9M |
| Total Debt | 14.2M | 15.8M | 12.0M | 8.41M | 652K | 694K | 582K | 273K | 116K | 34.3K |
| Cash Flow | ||||||||||
| Operating Cash Flow | -1.44M | -15.0M | -10.9M | -2.68M | -5.66M | -21.8M | -9.85M | -14.7M | 77.2K | -12.4M |
| Capital Expenditure | 248K | 358K | 69.3K | 5.29K | 1.10K | 1.54K | 0.25 | 0.00 | 0.00 | 4.00 |
| Free Cash Flow | -1.69M | -15.4M | -11.0M | -2.69M | -5.67M | -21.8M | -9.85M | -14.7M | 77.2K | -12.4M |
| Ratios | ||||||||||
| ROE | -16.7% | -147.9% | -54.6% | -56.1% | -18.3% | -40.3% | -219.7% | -88.6% | -1.9% | -54.7% |
| ROA | -8.0% | -38.6% | -18.0% | -20.7% | -16.0% | -35.1% | -165.9% | -56.0% | -1.3% | -46.9% |
| Net Profit Margin | -19.1% | -154.3% | -91.6% | -15,255.2% | -704.5% | -5,986.9% | - | - | -2.4% | -1,145.7% |
| Debt to Equity | 0.46x | 1.27x | 0.97x | 0.96x | 0.02x | 0.01x | 0.04x | 0.02x | 0.01x | 0.00x |
What these items mean
- Revenue
- Total sales of goods and services in the period.
- Gross Profit
- Revenue minus the direct cost of producing what was sold.
- Operating Income
- Profit from the core business after operating expenses.
- EBITDA
- Earnings before interest, taxes, depreciation and amortization.
- Net Income
- Profit left for shareholders after all expenses, interest and taxes.
- EPS
- Net income divided by shares outstanding.
- Total Assets
- Everything the company owns.
- Total Liabilities
- Everything the company owes.
- Shareholders' Equity
- Assets minus liabilities: the book value that belongs to shareholders.
- Cash & Short-term Investments
- Cash and investments that can be turned into cash quickly.
- Total Debt
- Short and long-term borrowings.
- Operating Cash Flow
- Cash generated by the core business.
- Capital Expenditure
- Cash spent on property, plant and equipment.
- Free Cash Flow
- Operating cash flow minus capital expenditure: cash left for dividends, buybacks or debt repayment.
- ROE
- Return on equity: net income divided by shareholders' equity.
- ROA
- Return on assets: net income divided by total assets.
- Net Profit Margin
- Net income as a share of revenue.
- Debt to Equity
- Total debt divided by shareholders' equity.
Neuphoria Therapeutics Inc dividends
Neuphoria Therapeutics Inc has not paid dividends in the last 10 fiscal years.
Last stock split: 1:12 on Dec 24, 2024.
Who owns Neuphoria Therapeutics Inc
- Insiders 5.02%
- Institutions 41.79%
- Public & others 53.19%
- Shares outstanding 5.41M
- Free float 5.37M
Top funds holding NEUP.US
| Holder | Shares | % of shares | Change | As of |
|---|---|---|---|---|
| AdvisorShares Psychedelics ETF | 291K | 5.37% | 0.00% | Oct 2026 |
| Vanguard MStar Total Stk Mkt Idx Invest | 110K | 2.04% | 0.00% | Sep 2026 |
| Fidelity Extended Market Index | 25.5K | 0.47% | -32.53% | Sep 2026 |
| Fidelity Series Total Market Index | 8.04K | 0.15% | 0.00% | Sep 2026 |
| Fidelity Total Market Index | 5.40K | 0.10% | 0.00% | Sep 2026 |
| Fidelity Nasdaq Composite Index | 2.43K | 0.04% | 0.00% | Aug 2026 |
Top institutions holding NEUP.US
| Holder | Shares | % of shares | Change | As of |
|---|---|---|---|---|
| Lynx1 Capital Management, LP | 875K | 16.18% | 0.00% | Jun 2026 |
| AdvisorShares Investments, LLC | 253K | 4.67% | +62.78% | Jun 2026 |
| Vanguard Capital Management, LLC | 173K | 3.21% | +76.10% | Jun 2026 |
| Shay Capital LLC | 156K | 2.88% | +3.19% | Jun 2026 |
| Balyasny Asset Management LLC | 142K | 2.63% | +0.03% | Jun 2026 |
| Citadel Advisors Llc | 72.6K | 1.34% | +275.35% | Jun 2026 |
| Geode Capital Management, LLC | 49.5K | 0.92% | -4.79% | Jun 2026 |
| Ikarian Capital, LLC | 47.4K | 0.88% | 0.00% | Jun 2026 |
| Vanguard Fiduciary Trust Co | 33.8K | 0.62% | +0.65% | Jun 2026 |
| ADAR1 Capital Management LLC | 30.0K | 0.55% | 0.00% | Jun 2026 |
| XTX Topco Ltd | 23.1K | 0.43% | 0.00% | Jun 2026 |
| HRT FINANCIAL LLC | 22.9K | 0.42% | 0.00% | Jun 2026 |
| Jane Street Group LLC | 14.9K | 0.28% | 0.00% | Jun 2026 |
| BOOTHBAY FUND MANAGEMENT, LLC | 14.0K | 0.26% | 0.00% | Jun 2026 |
| Commonwealth Equity Services, LLC | 11.2K | 0.21% | 0.00% | Jun 2026 |
| Northern Trust Corp | 10.6K | 0.20% | 0.00% | Jun 2026 |
| Merck & Co Inc | 10.0K | 0.19% | 0.00% | Jun 2026 |
| UBS Group AG | 2.12K | 0.04% | -8.59% | Jun 2026 |
| Morgan Stanley - Brokerage Accounts | 58.00 | 0.00% | 0.00% | Jun 2026 |
| Caitong International Asset Management Co., Limited. | 3.00 | 0.00% | 0.00% | Jun 2026 |
Neuphoria Therapeutics Inc company profile
- Company name
- Neuphoria Therapeutics Inc
- Ticker
- NEUP.US
- Exchange
- USA Stocks
- Listed since
- Dec 23, 2024
- Sector
- Healthcare
- Industry
- Biotechnology
- Employees
- 1
- Fiscal year end
- June
- Address
- 14 Milliston Road, Millis, MA, United States, 02054
- Phone
- 339 240 6066
- Website
- neuphoriatx.com
About Neuphoria Therapeutics Inc
Neuphoria Therapeutics Inc., a clinical stage biopharmaceutical company, develops novel allosteric ion channel modulators for patients with serious central nervous system disorders in Australia. Its lead product candidate is BNC210, an oral, proprietary, selective negative allosteric modulator of the alpha7 nicotinic acetylcholine receptor for post-traumatic stress disorder. The company also develops Merck alpha7 positive allosteric modulators. It has a research collaboration and license agreement with Merck & Co., Inc. to develop alpha7 receptor positive allosteric modulators targeting cognitive dysfunction associated with Alzheimer's disease and other central nervous system conditions. The company was formerly known as Bionomics Limited and changed its name to Neuphoria Therapeutics Inc. in December 2024. Neuphoria Therapeutics Inc. was incorporated in 1996 and is based in Millis, Massachusetts.
Neuphoria Therapeutics Inc management
5- Dr. Spyridon Papapetropoulos M.D., Ph.D.Interim CEO & Executive Director · born 1973
- Mr. Timothy M. Cunningham CPA, M.B.A.Fractional CFO · born 1962
- Dr. Julie Kerner Ph.D.Senior Vice President of Business Operations
- Mr. Adrian Hinton BEC, F.C.A.Financial Controller · born 1952
- Mr. Rajeev Chandra B.Com., C.A., M.B.A.Company Secretary